Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 5, 2010, Pages 905-911

  Matias, Patrícia João ^a,b,c   Jorge, Cristina ^a,b,c   Ferreira, Carina ^a,b,c   Borges, Marília ^d   Aires, Inês ^a,b,c   Amaral, Tiago ^a,b,c   Gil, Célia ^a,b,c   Cortez, José ^d,e   Ferreira, Aníbal ^a,b,c,e  

^a Hemodial Vila Franca de Xira Hemodialysis Center   (Portugal)

^b Núcleo de Investigação na Área Nefrológica ^*  (Portugal)

^c Núcleo de Investigação na Área Nefrológica   (Portugal)

^d Laboratório Dr Fernando Teixeira   (Portugal)

^e NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SERUM ALBUMIN; SEVELAMER;

ADULT; AGED; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREVALENCE; PROSPECTIVE STUDY; SUMMER; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WINTER;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; C-REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CHELATING AGENTS; CHOLECALCIFEROL; CHRONIC DISEASE; DIETARY SUPPLEMENTS; ERGOCALCIFEROLS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION MEDIATORS; KIDNEY DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 77952316154     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06510909     Document Type: Article

References (44)

1. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease: A single center observational study. Am J Nephrol 24: 503-510, 2004 (Pubitemid 39656665)
2. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM: Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033, 2005 (Pubitemid 40806515)
3. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialysed patients with chronic renal failure. Kidney Int 55: 1019-1027, 1999
4. Goodman WG, Coburn JW: The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43: 227-237, 1992
5. Schroeder NJ, Cunningham J: What's new in vitamin D for the nephrologist? Nephrol Dial Transplant 15: 460-466, 2000
6. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984 (Pubitemid 15197358)
7. Gomez-Alonso C, Naves-Diaz ML, Fernandez-Martin JL, Diaz-Lopez JB, Fernandez-Coto MT, Cannata-Andia JB: Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. Kidney Int Suppl S44-S48, 2003 (Pubitemid 36605861)
8. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J: The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 29: 3713-3720, 2009
9. Holick MF: Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79: 362-371, 2004
10. Andress DL: Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 69: 33-43, 2006
11. Jones G: Expanding role for vitamin D in chronic kidney disease: Importance of blood 25-OH-D levels and extrarenal 1α-hydroxylase in the classical and non-classical actions of 1α,25-dihydroxyvitamin D3. Semin Dial 20: 316-324, 2007
12. Kristal-Boneh E, Froom P, Harari G, Ribak J: Association of calcitriol and blood pressure in normotensive men. Hypertension 30: 1289-1294, 1997 (Pubitemid 27476193)
13. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure. J Am Coll Cardiol 41: 105-112, 2003 (Pubitemid 36044411)
14. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F: Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613-620, 2007
15. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 24: 611-618, 2009
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl S1-S130, 2009
17. Bushinsky DA, Monk RD: Electrolyte quintet: Calcium. Lancet 352: 306-311, 1998
18. Matias P, Jorge C, Aires I, Lage H, Gil C, Gomes F, Arranhado E, Ferreira A: Brain natriuretic peptide levels predict morbidity and mortality in haemodialysis patients. Port J Nephrol Hypertens 23: 249-255, 2009
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57: 450-458, 1986 (Pubitemid 16119719)
20. Hollis BW: Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135: 317-322, 2005
21. Sato T: Renal bioactivation of vitamin D and its key modulators. Clin Calcium 17: 686-690, 2007
22. Lambert PW, Stern PH, Avioli RC, Brackett NC, Turner RT, Greene A, Fu IY, Bell NH: Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man. J Clin Invest 69: 722-725, 1982
23. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Evidence for persistent vitamin d 1-alpha-hydroxylation in hemodialysis patients: Evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110: c58-c65, 2008
24. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E: Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72: 157-164, 1991 (Pubitemid 21921670)
25. Hewison M, Zehnder D, Bland R, Stewart PM: 1 Alpha-hydroxylase and the action of vitamin D. J Mol Endocrinol 25: 141-148, 2000
26. Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289: F8-F28, 2005
27. Mosekilde L: Vitamin D and the elderly. Clin Endocrinol (Oxf) 62: 265-281, 2005
28. Lips P: Vitamin D physiology. Prog Biophys Mol Biol 92: 4-8, 2006
29. Jones G, Vriezen D, Lohnes D, Palda V, Edwards NS: Side-chain hydroxylation of vitamin D3 and its physiological implications. Steroids 49: 29-53, 1987 (Pubitemid 18088688)
30. Makin G, Lohnes D, Byford V, Ray R, Jones G: Target cell metabolism of 1,25-(OH)2D3 to calcitroic acid: Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 262: 173-180, 1989 (Pubitemid 19220946)
31. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ: 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70: 654-659, 2006 (Pubitemid 44215339)
32. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C: Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure: A synergistic effect with r-HuEpo. Nephron Clin Pract 95: c121-c127, 2003
33. Mathieu C, Jafari M: Immunomodulation by 1,25-dihydroxyvitamin D3: Therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol 66: 275-283, 2006 (Pubitemid 44541215)
34. Seibert E, Levin NW, Kuhlmann MK: Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int 9[Suppl 1]: S25-S29, 2005
35. Targher G, Bertolini L, Padovani R, Zenari L, Scala L, Cigolini M, Arcaro G: Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) 65: 593-597, 2006 (Pubitemid 44583818)
36. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Daily oral 25-hydroxycholecalciferol supplementation for vitamin d deficiency in haemodialysis patients: Effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23: 3670-3676, 2008
37. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: c132-c138, 2007
38. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
39. Racek J, Králová H, Trefil L, Rajdl D, Eiselt J: Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 103: c162-c172, 2006
40. Zeng C, Wei T, Jin L, Wang L: Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J 36: 552-557, 2006
41. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 339: 321-328, 1998
42. Nitta K, Kawashima A, Yumura W, Naruse M, Oba T, Kabaya T, Nihei H: Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol 18: 411-415, 1998
43. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J: Vitamin D: A negative endocrine regulator of the reninangiotensin system and blood pressure. J Steroid Biochem Mol Biol 89: 387-392, 2004
44. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-age men. Am J Hypertens 8: 894-901, 1995